目的 觀察清肺消炎丸聯(lián)合莫西沙星治療社區(qū)獲得性肺炎的臨床療效和安全性.方法 選取2013年3月—2014年4月天津市第二醫(yī)院收治的社區(qū)獲得性肺炎患者90例,隨機(jī)分為對(duì)照組(45例)和治療組(45例).對(duì)照組靜脈滴注鹽酸莫西沙星氯化鈉注射液,0.4 g/次,1次/d;治療期間若病情好轉(zhuǎn),抗生素可改為鹽酸莫西沙星片0.4 g/次,1次/d.治療組在對(duì)照組治療的基礎(chǔ)上,口服清肺消炎丸60粒/次,3次/d.兩組均連續(xù)治療10 d.治療后,評(píng)價(jià)兩組的臨床療效,同時(shí)比較患者臨床癥狀、體征以及實(shí)驗(yàn)室療效指標(biāo)的變化.結(jié)果 治療組和對(duì)照組愈顯率分別為93.33%、80.00%,兩組愈顯率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05).治療組患者退熱、咳嗽咳痰緩解、肺部啰音消失情況優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05).兩組患者治療第3、10天白細(xì)胞計(jì)數(shù)、中性粒細(xì)胞比例及C反應(yīng)蛋白(CRP)均較治療前顯著下降,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);治療組在治療第3、10天CRP低于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05).結(jié)論 清肺消炎丸聯(lián)合莫西沙星治療社區(qū)獲得性肺炎具有較好的臨床療效,可改善患者癥狀和實(shí)驗(yàn)室檢查,且無不良反應(yīng),值得臨床推廣應(yīng)用.

Objective To observe the clinical efficacy and safety of Qingfei Xiaoyan Pills combined with moxifloxacin in treatment of community acquired pneumonia. Methods Patients (90 cases) with community acquired pneumonia who came to the Second Hospital of Tianjin from March 2013 to April 2014 were randomly divided into control (45 cases) and treatment (45 cases) groups. The patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection (0.4 g/time), once daily. If the patients got better during the treatment, antibiotics could be changed to Moxifloxacin Hydrochloride Tablets, 0.4 g/time, once daily. The patients in the treatment group were po administered with Qingfei Xiaoyan Pills on the basis of control group, 60 grains/time, three times daily. The patients in two groups were treated for 10 d. After treatment, the treatment efficacy was evaluated, while the changes of clinical symptoms, signs, and laboratory indexes were compared. Results The markedly effective rate in the treatment and control groups were 93.33% and 80.00%, respectively, and there were differences between the two groups (P < 0.05). Defervescence, ease of cough and expectoration, and situation of lung sound disappeared in treatment group were better than those in the control group, with the significant difference between two groups (P < 0.05). The count of white blood cells, neutrophils ratio, and CRP decreased significantly in two groups on days 3 and 10 of treatment, and the difference was statistically significant in the same group (P < 0.05). CRP in the treatment group was lower than that in the control group on days 3 and 10 of treatment, with the significant difference between two groups (P < 0.05). Conclusion Qingfei Xiaoyan Pills combined with moxifloxacin has good clinical effect in treatment of community acquired pneumonia, and can improve symptoms and laboratory examination with no adverse reactions, which is worthy of clinical application.